[1] Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635–41.
[2] Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 1992;102(4 Suppl):445S−55S.
[3] Schmitt L, Speckman J, Ansell J Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003;15(3):213–216.
[4]Helmut Baumgartner,Volkmar Falk, Jeroen J et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal 2017; 38, 2770–2771.
[5] Uetsuka Y, Hosoda S, Kasanuki H, Aosaki M, Murasaki K, Ooki K, et al. Optimal therapeutic range for oral anticoagulants in Japanese patients with prosthetic heart valves: a preliminary report from a single institution using conversion from thrombotest to PT-INR. Heart Vessels 2000;15:124−8.
[6] Sun X, Hu S, Qi G, Zhou Y. Low standard oral anticoagulation therapy for Chinese patients with St. Jude mechanical heart valves. Chin Med J (Engl) 2003;116:1175−8.
[7] Xu JP, Shi YK, Dong L, Wei Y, Fu B, Liu RF. Low intensity anticoagulation therapy for chinese population with heart valve replacement–3 000 cases follow-up. J Sichuan Univ (Med Sci Edi) 2016; 47: 90–2.
[8] Zhou XM, Zhuang W , Hu JG , et al. Low-Dose Anticoagulation in Chinese Patients with Mechanical Heart Valves. Asian Cardiovasc Thorac Ann 2005;13:341–4
[9] Rosendaal F, Cannegieter S, Van der Meer F, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.
[10] Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B et al Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 2018;154(5):1121–1201.
[11] Jones C,Pollit V,Fitzmaurice D,et a1.The management of atrial fibrillation:summary of updated NICE guidance. BMJ 2014;348:g3655.
[12] Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013;144:1555-1563.
[13] Sun JC, Davidson MJ, Lamy A ,et al., Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009;374,565–576.
[14] Cannegieter SC, Rosendaal FR, Briët E, Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89,635–641.
[15] Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70(2):252–89.
[16] Emery RW, Emery AM, Raikar GV, et al. Anticoagulation for mechanical heart valves: a role for patient based therapy. J Thromb Thrombolysis 2008;25:18-25.
[17] Connolly SJ, Pogue J, Eikelboom J, et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries a s measured by time in therapeutic range. Circulation 2008; 118:2029-37.
[18] Chan PH, Hai JJ, Chan EW, et al. Use of the SAMe-TT2R2 score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence. PLoS One 2016; 11:e0150674
[19] Fernando PJ, Rafael SS, Lucas R,et al. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events.Arq Bras Cardiol 2017 Apr;108(4):290-296.
[20] Krittayaphong R, Winijkul A, Pirapatdit A,et al. SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation.Singapore Med J,2019 Nov 4.doi: 10.11622/smedj.2019143.
[21] van Miert J, Bos S, Veeger N,et al. Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. PloS One 2018;13(3):e0194208.
[22] FU B,DONG L,Shi YK.Construction of an Anticoagulation Therapy Database of Chinese Patients after Heart Valve Replacement. Chin J Clin Thorac Cardiovasc Surg 2013;20(1):3-5.
[23] Oldgren J, Healey J S, Ezekowitz M, et a1. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries:the RE-LY Atrial Fibrillation Registry. Circulation 2014,129(15):1568-1576.
[24] Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thrombosis and haemostasis 2014; 111(5):789–797.